Clinical Studies and Protocols
Site Map Investigators Log-inClinical Studies and Protocols
Click below for more details or search for keywords above
(JKR-0937) Secukinumab in Mild Psoriasis


Safety and Efficacy of Secukinumab in Adults with Chronic Plaque Type Psoriasis with a PASI score of 6 to 12
Principal Investigator:
James G. Krueger M.D., Ph.D.
Investigators:
Contact Information:
Principal Investigator:
James G. Krueger M.D., Ph.D.
Investigators:
Contact Information:
Recruitment Specialist
1230 York Ave
New York , NY 10065
1230 York Ave
New York , NY 10065
Telephone: 1(800)782-2737
Email: rucares@rockefeller.edu
Email: rucares@rockefeller.edu
Enrollment Status:
Open to Enrollment
Brief Summary of Protocol:
Mild psoriasis not only progresses to moderate-to-severe psoriasis but also precedes systemic inflammation that leads to psoriatic arthritis and cardiovascular comorbidities. By curing mild psoriasis with a short-term anti-IL-17A treatment, we may reduce the costs of treating psoriasis and associated medical conditions, including psoriatic arthritis, cardiovascular disease, and diabetes.
Detailed Description of Protocol:
What specifically makes a person eligible for the study?
You may be eligible to enter this study:
• Blood tests • Skin biopsies • Receipt of the study medication
Gender:
Both
Age(s):
At least 18 years old
Children permitted to participate:
No
Potential Benefits.....
Compensation:
Compensation is provided
Open to Enrollment
Brief Summary of Protocol:
Mild psoriasis not only progresses to moderate-to-severe psoriasis but also precedes systemic inflammation that leads to psoriatic arthritis and cardiovascular comorbidities. By curing mild psoriasis with a short-term anti-IL-17A treatment, we may reduce the costs of treating psoriasis and associated medical conditions, including psoriatic arthritis, cardiovascular disease, and diabetes.
Detailed Description of Protocol:
What specifically makes a person eligible for the study?
You may be eligible to enter this study:
• Blood tests • Skin biopsies • Receipt of the study medication
Gender:
Both
Age(s):
At least 18 years old
Children permitted to participate:
No
Potential Benefits.....
Compensation:
Compensation is provided